Lev Demidov

16.1k total citations · 4 hit papers
141 papers, 5.3k citations indexed

About

Lev Demidov is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Lev Demidov has authored 141 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Oncology, 74 papers in Molecular Biology and 27 papers in Immunology. Recurrent topics in Lev Demidov's work include Melanoma and MAPK Pathways (59 papers), Cutaneous Melanoma Detection and Management (48 papers) and CAR-T cell therapy research (34 papers). Lev Demidov is often cited by papers focused on Melanoma and MAPK Pathways (59 papers), Cutaneous Melanoma Detection and Management (48 papers) and CAR-T cell therapy research (34 papers). Lev Demidov collaborates with scholars based in Russia, United States and Australia. Lev Demidov's co-authors include James Larkin, Claus Garbe, Brigitte Dréno, Caroline Robert, Paolo A. Ascierto, Daniil Stroyakovskiy, Grant A. McArthur, Reinhard Dummer, Piotr Rutkowski and Caroline Dutriaux and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Lev Demidov

121 papers receiving 5.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma

2014 1.5k citations James Larkin, Paolo A. Ascierto et al. profile →
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

2012 1.1k citations Caroline Robert, Claus Garbe et al. profile →
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

2019 703 citations Jean‐Jacques Grob, Lev Demidov et al. profile →
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

2020 442 citations Ralf Gutzmer, Daniil Stroyakovskiy et al. profile →

Peers

Countries citing papers authored by Lev Demidov

Since Specialization

Citations

This map shows the geographic impact of Lev Demidov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lev Demidov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lev Demidov more than expected).

Fields of papers citing papers by Lev Demidov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lev Demidov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lev Demidov. The network helps show where Lev Demidov may publish in the future.

Co-authorship network of co-authors of Lev Demidov

This figure shows the co-authorship network connecting the top 25 collaborators of Lev Demidov. A scholar is included among the top collaborators of Lev Demidov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lev Demidov. Lev Demidov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Changes in clinical guidelines of 2023 and 2025 on treatment of cutaneous and mucosal melanoma 2025 ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Andrey Golanov, Lev Demidov, (unknown), Andrew R. Zaretsky, (unknown), (unknown), (unknown), (unknown), (unknown), А. А. Феденко, (unknown), (unknown), (unknown)	0
2	1100P Anti-PD1 + low-dose anti-CTLA4 immunotherapy pathological response rate in patients with stage III resectable melanoma: Phase III NEOMIMAJOR trial interim analysis 2024 ·Annals of Oncology ·(unknown), Lev Demidov, (unknown), (unknown), Vadim Kozlov, (unknown), (unknown), Natalia Fadeeva, (unknown), (unknown), Daniil Stroyakovskiy, (unknown), Anastasia Mochalova, Alexander S. Sobolev, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
3	Prognostic fine needle aspiration biopsy of uveal melanoma: Molecular and genetic factors of metastasis risk 2023 ·SHILAP Revista de lepidopterología ·V.А. Yarovaya, (unknown), Andrew R. Zaretsky, (unknown), (unknown), (unknown), Lev Demidov, А.А. Yarovoy	1
4	LBA39 Final 5-year results of the phase II, multicenter, randomized, open-label trial of talimogene laherparepvec (T-VEC) neoadjuvant treatment (Tx) plus surgery vs immediate surgery in patients (pts) with resectable stage IIIB-IVM1a melanoma (MEL) 2022 ·Annals of Oncology ·R. Dummer, David Gyorki, John Hyngstrom, (unknown), (unknown), Lev Demidov, (unknown), T. Lawrence, Mark B. Faries, Merrick I. Ross	2
5	Immunotherapy in Combination with Radiation Therapy in the Treatment of Patients with Squamous Cell Skin Cancer 2022 ·Effective Pharmacotherapy ·(unknown), (unknown), (unknown), (unknown), Lev Demidov, (unknown)	1
6	5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study 2021 ·Clinical Cancer Research ·Paolo A. Ascierto, Brigitte Dréno, James Larkin, Antoni Ribas, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, L. Thomas, Luis de la Cruz‐Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Jessie J. Hsu, (unknown), Haocheng Li, Edward McKenna, Athina Voulgari, Grant A. McArthur	119
7	Pigmented skin neoplasm in a child: сomplex case report and review of the literature 2020 ·(unknown), Т. В. Наседкина, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), И. С. Абрамов, Lev Demidov, (unknown)	0
8	Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials 2020 ·European Journal of Cancer ·Axel Hauschild, Paolo A. Ascierto, Dirk Schadendorf, Jean‐Jacques Grob, Antoni Ribas, Felix Kiecker, Caroline Dutriaux, Lev Demidov, Célèste Lebbé, Piotr Rutkowski, Christian U. Blank, Ralf Gutzmer, Michael Millward, Richard Kefford, T Haas, Anthony M. D’Amelio, Eduard Gasal, Bijoyesh Mookerjee, Paul B. Chapman	50
9	1102P Clinical benefit in BRAFV600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: Exploratory analyses from the IMspire150 study 2020 ·Annals of Oncology ·Paolo A. Ascierto, Caroline Robert, Karl D. Lewis, Ralf Gutzmer, Daniil Stroyakovskiy, Helen Gogas, Светлана Проценко, Rodrigo Perez Pereira, Thomas Eigentler, Piotr Rutkowski, Lev Demidov, Georgy M. Manikhas, (unknown), (unknown), Kalpit Shah, Yuanliang Yan, Grant A. McArthur	5
10	Basal cell cancer treatment. Therapeutic experience with vismodegib therapy 2018 ·Meditsinskiy sovet = Medical Council ·(unknown), Lev Demidov	2
11	MOLECULAR TESTING OF STAGE I-III UVEAL MELANOMA IN THE CONTEXT OF CONSERVATIVE OR SURGICAL TREATMENT: OUR EXPERIENCE 2018 ·Voprosy Onkologii ·(unknown), V.А. Yarovaya, (unknown), Lev Demidov, А.А. Yarovoy, (unknown)	2
12	PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA 2017 ·Meditsinskiy sovet = Medical Council ·(unknown), Lev Demidov	0
13	BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk for recurrence 2017 ·Annals of Oncology ·(unknown), Michele Maio, Lev Demidov, Mario Mandalà, Paolo A. Ascierto, (unknown), Andrzej Maćkiewicz, Piotr Rutkowski, Alex Guminski, (unknown), Bryony Simmons, (unknown), (unknown), Dirk Schadendorf	6
14	Transarterial chemoembolization for patients with metastatic uveal melanoma in the liver 2016 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), Lev Demidov, (unknown), (unknown), (unknown)	0
15	Спектр мутаций онкогенов различается в субтипах меланомы кожи 2015 ·Молекулярная биология ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Lev Demidov	2
16	Лизомустин - отечественный препарат из группы производных нитрозомочевины в лечении меланомы кожи 2014 ·Vera Gorbunova, (unknown), Lev Demidov, (unknown)	1
17	Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine 2014 ·Annals of Oncology ·Jean‐Jacques Grob, Mayur M. Amonkar, Salvador Martín‐Algarra, Lev Demidov, Vicki Goodman, Kelly M. Grotzinger, Patricia Haney, Eckhart Kämpgen, Bogusława Karaszewska, Cornelia Mauch, Wilson H. Miller, Michael Millward, Beloo Mirakhur, Piotr Rutkowski, Vanna Chiarion‐Sileni, S. Swann, Axel Hauschild	37
18	Определение специфических противоопухолевых антител у больных диссеминированной меланомой в процессе вакцинотерапии 2012 ·(unknown), Е. В. Степанова, (unknown), (unknown), (unknown), И. Н. Григорьева, (unknown), (unknown), (unknown), (unknown), (unknown), Lev Demidov, (unknown)	3
19	Hypercoagulability as a prognostic factor for survival in patients with metastatic renal cell carcinoma 2009 ·Journal of Experimental & Clinical Cancer Research ·Ilya Tsimafeyeu, Lev Demidov, (unknown), (unknown), (unknown)	30
20	Adjuvant Fermented Wheat Germ Extract (Avemar ^™ ) Nutraceutical Improves Survival of High-Risk Skin Melanoma Patients: A Randomized, Pilot, Phase II Clinical Study with a 7-Year Follow-Up 2008 ·Cancer Biotherapy and Radiopharmaceuticals ·Lev Demidov, (unknown), (unknown), (unknown), (unknown)	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact